In many cancers, a high constitutive activation of transcription factor NF-jB has been implicated in tumor progression and apoptosis resistance, making NF-jB an attractive target for cancer therapy. Here, we describe the specific inhibition of NF-jB by the intracellular delivery of IjBa through VP22-mediated protein transduction. The Herpes virus protein VP22 has attracted great attention in gene therapy, because of its ability to migrate from an original expressing cell into surrounding recipient cells, resulting in high levels of protein transduction. To evaluate the use of VP22 as a vehicle for NF-jB inhibition, we expressed several versions of VP22-IjBa fusion proteins in baculovirus, bacteria, and mammalian cells. While we could not detect transcellular migration of different VP22-IjBa constructs, interestingly, baculovirally expressed VP22-IjBa was efficiently delivered into cells after exogenous administration. The purified and imported VP22-IjBa retained its function and efficiently inhibited both constitutive and inducible NF-jB activation. We further show that the 34 C-terminal amino acids of VP22 were sufficient for the import property, suggesting also that the ability of intercellular migration and cellular import are not linked to each other. Together, our results demonstrate that recombinant VP22 acts as an efficient vehicle for the exogenous delivery of IjBa and, moreover, might find applications to block NF-jB activation specifically.
In most tissues, the activity of the transcription factor NF-kB is tightly controlled by cytoplasmic sequestration through interaction with inhibitory IkB proteins, from which IkBa is the most prominent member. Almost all stimuli that induce NF-kB activation lead to phosphorylation of IkBa through the IkB kinase (IKK) complex. This modification marks IkBa for polyubiquitination and subsequent degradation through the 26S proteasome. The freed NF-kB translocates to the nucleus and regulates the transcription of NF-kBresponsive genes (Karin and Lin, 2002) . Besides its key regulatory function in the immune system, NF-kB plays an important role in a variety of physiological processes including cell growth, differentiation, cell cycle regulation, and apoptosis. Therefore, it is not surprising that malfunctions in the strict control system of NF-kB activity are linked to severe pathological conditions such as chronic inflammation and neoplastic transformation (Aradhya and Nelson, 2001) .
Many types of lymphoid malignancies, breast, colon, liver, pancreatic, prostate, bladder, and lung carcinoma are associated with high constitutive activation of NFkB (Rayet and Gelinas, 1999) . The permanent NF-kB activation contributes actively to tumorigenesis, because under most circumstances NF-kB promotes cell cycle progression and inhibits apoptosis, supports tumor angiogenesis, and induces matrix metalloproteinases (Garg and Aggarwal, 2002) . Moreover, NF-kB is held responsible, at least in part, for chemoresistance because of the induction of apoptosis inhibitors and multidrug resistance proteins (Zhou and Kuo, 1997; Karin and Lin, 2002) . Therefore, inhibition of NF-kB seems to be a promising therapeutic approach for the treatment of cancers. However, so far, therapeutic applications are limited because of the lack of sufficient specificity and bioavailability of the NF-kB-inhibitory compounds.
In the present study, we describe the inhibition of NF-kB by taking advantage of protein transduction. This novel technology offers an alternative to classical gene therapy if a short-term, specific, and efficient accumulation of a gene product is required (Ford et al., 2001) . Certain proteins are able to cross biological membranes and this property is mediated by short, basic motives, the so-called protein transduction domains (PTDs) . A protein of interest fused to these proteins or their PTD is taken up into cells under preservation of its biological activity (Schwarze and Dowdy, 2000) . Among the well-characterized proteins with transduction potential including the HIV-1 Tat protein or the Drosophila Antennapedia homeodomain, VP22, a tegument protein of Herpes simplex virus type-I, has the additional property of transcellular migration (Elliott and O'Hare, 1997) . The molecular mechanism involved in this shuttle effect is poorly understood, but it has been shown that some fusion proteins retain the capacity of intercellular migration. When expressed in mammalian cells, certain VP22 fusion proteins are exported from transfected cells and taken up by surrounding, nontransfected cells, where they accumulate in the nucleus. This transcellular migration, termed 'spread', might enhance the efficiency of gene therapy and enable the very effective delivery of heterologous proteins into target cells.
To achieve an efficient and specific NF-kB inhibition, we created several N-and C-terminal fusions of VP22 with IkBa in the frame of a C-terminal CMV-epitope tag. Similar constructs were produced with an IkBa mutant (D N IkBa) lacking the 69 N-terminal regulatory amino acids (Figure 1a ). This mutant acts as a superrepressor of NF-kB, because it is not degraded by the proteasome in response to cell stimulation. Following transfection in MCF-7 cells, all VP22 fusion proteins were readily detectable by Western blot analyses with anti-CMV-tag and anti-IkBa antibodies (data not shown). The VP22-IkBa proteins were potent inhibitors of NF-kB activation, as they completely blocked the binding of NF-kB to its DNA consensus sequence after TNFa stimulation in gelshift assays (Figure 1b ). This proved that IkBa had not lost its structural and functional integrity after fusion with VP22 and was still able to interact with NF-kB. However, although all proteins were expressed and retained their activity, we could not observe a spread of the expressed VP22-IkBa proteins from originally transfected cells to nontransfected neighbor cells. In indirect immunofluorescence stainings, VP22-IkBa and VP22-D N IkBa were exclusively found in the cytoplasm of transfected cells, but we were unable to detect transcellular migration (Figure 1c) . In contrast, wild-type VP22 alone displayed the typical spreading pattern where the migrated proteins localized to the nuclei (Figure 1c ). The orientation of the VP22 fusion had no influence on the transcellular migration of the activity of IkBa (data not shown).
Next we investigated whether the VP22-IkBa proteins are able to enter cells after exogenous application, thus showing classical protein transduction properties. Whole-cell extracts were prepared under detergent-free conditions from 293 cells expressing the recombinant proteins and added to complete medium of Cos-1 cells. Incubation for 15 min was already sufficient to observe a specific uptake of VP22 and VP22-IkBa (Figure 2a) . A more detailed analysis revealed that some portion of the imported VP22-IkBa was localized in granular structures that were spread over the cell (Figure 2b ). Nevertheless, the protein was a potent inhibitor of NF-kB Figure 1 VP22-IkBa inhibits NF-kB activation, but does not display intercellular transmigration activity. (a) Eukaryotic expression constructs. Different eukaryotic expression vectors for wild-type VP22 and IkBa, or fusions of VP22 with IkBa or D N IkBa were generated and transfected with lipofectamine (Gibco-BRL). The parental vector pc49ep-2 had a pcDNA1.1 backbone and was derived from the plasmid pc49epB (Phelan et al., 1998) . It contained the VP22 reading frame flanked at its N and C termini by a unique BglII and BamH1 site, respectively. The VP22 coding region reads in frame to the sequence of a CMV epitope tag. The coding regions for IkBa and D N IkBa were cloned into the BamH1 site for C-terminal fusions (VP22-IkBa/VP22-D N IkBa) or the BglII site for N-terminal fusions (IkBa-VP22/D N IkBa-VP22). The orientation of the VP22 fusion did not affect the uptake or biological activity of IkBa (data not shown). (b) Effect on NF-kB activation: 40 h after transfection with the indicated expression constructs HeLa cells were stimulated with TNFa (20 ng/ml) for 20 or 240 min, and nuclear extracts were analysed for active NF-kB by gelshift assays as described (Goebeler et al., 1995; Wesselborg et al., 1997) . The NF-kB DNA complex, consisting of a p50/RelA heterodimer as assessed by supershift analysis (data not shown), is indicated by an arrowhead. A faster migrating nonspecific complex that served as a control for equal protein loading is marked by a circle. (c) Intracellular localization of the fusion proteins: 48 h after transfection with VP22, VP22-IkBa, or the control vector, MCF-7 cells were fixed, permeabilized and the expressed proteins were detected with an anti-CMV epitope antibody (Capricorn Products). After incubation with an OregonGreen TM 488-coupled secondary antibody (Molecular Probes), immunostained cells were analysed by confocal laser scan microscopy. Expressed VP22 shows a characteristic spread from transfected cells (arrows) into nontransfected neighbor cells. VP22-IkBa and VP22-D N IkBa do not undergo transcellular migration Specific inhibition of NF-jB through VP22-IjBa C Stroh et al activation, which was demonstrated by a markedly decreased DNA binding of NF-kB after its exogenous supply and TNFa stimulation ( Figure 2c ). These results encouraged us to proceed with the classical protein transduction approach and we looked for an expression system for VP22-IkBa to perform import studies with highly purified proteins. Consistent with other reports (Kueltzo et al., 2000; Normand et al., 2001) , we were unable to express full-length VP22 and VP22-IkBa in E. coli. It was, however, possible to express bacterially and purify GST-tagged VP22 and VP22-IkBa proteins with truncated versions of VP22, either comprising aa 160-301 (VP22D159) or the last C-terminal 34 aa (VP22D267) (Figure 3a) . The fulllength GST-tagged proteins were not or only marginally imported after exogenous application to MCF-7 cells (data not shown), most likely because of the interference of GST with VP22 sequence stretches necessary for membrane translocation. However, after removal of the GST-tag, the proteins were efficiently taken up into MCF-7 cells within minutes. The achieved level of the imported proteins was comparable to or even higher than the level of endogenous IkBa (Figure 3b ). Similar results were obtained with VP22D159-D N IkBa and VP22D267-D N IkBa. The presence or omission of fetal calf serum had no influence on the uptake (data not shown). Thus, we demonstrated that the C-terminal 34 aa were sufficient for the vehicle function of VP22, although the longer variants yielded a more efficient uptake ( Figure 3b ).
When added to TNF-treated MCF-7 cell extracts, 1 ng of VP22D159-IkBa was able to block the binding of active NF-kB to its consensus sequence as efficiently as IkBa, demonstrating that the purified protein was biologically active (Figure 3c ). Higher amounts of VP22D159-D N IkBa, but not of the VP22D267 constructs, were also able to inhibit DNA binding of NFkB in these in vitro assays (data not shown). However, despite the high intracellular accumulation of VP22D159-IkBa, we were unable to detect an inhibition of NF-kB in vivo after TNF stimulation (Figure 3d ). Indirect immunofluorescence studies revealed that the imported VP22D159-IkBa accumulated within granular structures inside the cell (Figure 3e ), similar to those observed after uptake of nonpurified VP22-IkBa from cell extracts (Figure 2b ). Unlike VP22-IkBa, the purified recombinant VP22D159-IkBa seemed to be exclusively localized in these structures. Strikingly similar granular structures have recently been reported to occur in cells when recombinant VP22 consisting of the C-terminal half was incubated with oligonucleotides in an antisense-DNA delivery study (Normand et al., 2001) . It was postulated that the basic VP22 protein formed aggregates with the oligonucleotides via electrostatic interaction. Since IkBa is a highly acidic protein, VP22D159-IkBa has a dipole character and could aggregate in the same manner.
The experiments with bacterially expressed VP22D159-IkBa showed that also highly purified VP22-IkBa fusion proteins were specifically and efficiently taken up by cells. However, the necessity to express a truncated version of VP22 in E. coli led to a higher tendency of VP22D159-IkBa to form aggregates compared to full-length VP22-IkBa. This was presumably the reason for the inability of VP22D159-IkBa to interact with NF-kB, even though high intracellular levels of protein import were achieved. We therefore sought for another possibility to obtain purified fulllength VP22-IkBa. Stable or transient expression in 293 or Sf-9 insect cells yielded in too low amounts of the protein for purification (data not shown). The only system enabling us to express and purify VP22-IkBa was Figure 2 Exogenous VP22-IkBa is imported into cells, where it inhibits NF-kB activation. (a) At 48 h after transfection with VP22, VP22-IkBa, or IkBa, cell extracts were prepared from 293 cells in the absence of detergents as described (Ferrari et al., 1999) . Extracts from 3 Â 10 5 cells were then added to Cos-1 cells in a 35 mm dish. After 15 min, the cells were washed at least four times and processed for immunocytochemistry. Imported recombinant proteins were detected with anti-VP22 (provided by W Wybranietz) or anti-IkBa (Santa Cruz) and rhodamine-coupled secondary antibodies (Molecular Probes) and detected by confocal laserscan microscopy. Specific inhibition of NF-jB through VP22-IjBa C Stroh et al baculoviral expression of the His-tagged protein in Sf-9 insect cells. VP22-IkBa as well as the single proteins VP22 and IkBa alone were readily expressed in this system and could be purified to near homogeneity by metal chelate and ion exchange chromatography (Figure 5a ), although the expression of VP22-IkBa resulted in lower yields (data not shown). Like nonpurified VP22-IkBa and bacterially expressed VP22D159-IkBa, recombinant VP22-IkBa purified from baculovirus-infected insect cells was efficiently and specifically imported into MCF-7 cells after exogenous application (Figure 4) . Indirect immunofluorescence staining further revealed that the full-length baculoviral VP22-IkBa had a less pronounced tendency to aggregate than VP22D159-IkBa. When added exogenously to TNF-treated cell extracts, 1 ng of VP22-IkBa completely blocked the binding of activated NF-kB to its consensus sequence (Figure 5a ). More importantly, with reducing the accumulation in intracellular granular structures, the imported VP22-IkBa gained potent NF-kB inhibitory potential in intact cells. When MCF-7 cells were incubated with VP22 and VP22-IkBa, both proteins were imported and could be detected in cell extracts after 15 min of incubation (Figure 5b, right panel) . In agreement with the immunofluorescence data (Figure 4 ), we found a slightly better uptake of 'naked' VP22 compared to VP22-IkBa. VP22-IkBa, unlike unfused VP22, did however completely inhibit NF-kB activation in response to TNF stimulation (Figure 5b, left panel) . Almost no uptake and inhibition of NF-kB DNA binding were observed when unfused IkBa was incubated with the cell cultures (data not shown). We also analysed the NF-kB-inhibitory potential of VP22-IkBa in H21 cells, a HeLa cell line with constitutive NF-kB activation. Both exogenously supplied VP22 and VP22-IkBa were readily imported into the cells (Figure 5c) . The achieved intracellular level of VP22-IkBa was sufficient to remarkably reduce the high basal activity as well as the TNF-induced activation of NF-kB in H21 cells. Together, although VP22-IkBa does not display intercellular migration, baculovirally expressed VP22 fusion proteins therefore act as efficient vehicles for the Up to now, several approaches have been reported to inhibit transcription factor NF-kB with the aim to develop a treatment for chronic inflammatory diseases or cancers, either as an adjuvant or an alternative to classical therapeutic strategies. Several clinically used compounds including antioxidants, glucocorticoids, or nonsteroidal anti-inflammatory drugs inhibit NF-kB activation and thereby exert their anti-inflammatory effects. However, in most cases, these drugs either indirectly inhibit NF-kB or act rather upstream in the NF-kB signaling pathway (Schenk et al., 1994; Epinat and Gilmore, 1999; Makarov, 2000) . Also, recently described compounds that block inducible IkBa phosphorylation (Pierce et al., 1997) , peptides that prevent nuclear translocation of NF-kB (Fujihara et al., 2000) , or inhibition of IkBa ubiquitinylation (Swinney et al., 2002) lack a high specificity. Therefore, in addition to NF-kB, these approaches will also interfere with several Figure 4 Baculovirally expressed VP22-IkBa is efficiently taken up into mammalian cells. VP22, IkBa, and VP22-IkBa were cloned into pBlueBacHis2A (Invitrogen) and baculovirus particles were produced by homologous recombination. Following infection of Sf-9 cells, the proteins were purified by metal chelate and anion exchange chromatography (see Figure 5a ). MCF-7 cells in a 35 mm dish were then incubated for 20 min with 3 mg of the indicated proteins in complete medium. Imported proteins were detected by anti-IkBa or an anti-(His) 6 -epitope antibody (Invitrogen) and secondary rhodamine-coupled antibodies. The figure shows that VP22 and VP22-IkBa, but not wildtype IkBa, were efficiently imported into cells In vitro test of the ability of the baculovirally expressed proteins to interact with and to inhibit NF-kB as described in Figure 3b . The right panel shows a Coomassie Blue staining of an SDS gel with the purified proteins that were used in the experiments. (b,c) Import and inhibition of NF-kB activation in intact cells. MCF-7 cells (b) and HeLa H21 cells (c) cultured in a 35 mm dish were incubated for 15 min with 3 or 10 mg of the highly purified VP22 or VP22-IkBa proteins, respectively. Half of the samples were then treated for another 15 min with TNFa (20 ng/ml). After extensive washing, total cell extracts were prepared and analysed for NF-kB activation by gelshift assays (left panels). Activated NF-kB is marked by an arrowhead, the nonspecific DNA band with a circle. Right panels: Western blot analyses of cell extracts after incubation of cells with the recombinant proteins. Imported proteins were detected by an anti-(His) 6 -epitope antibody. The figure shows that both VP22 and VP22-IkBa were imported into cells, but only VP22-IkBa inhibited both the constitutive and inducible NF-kB activation. No significant import and NF-kB inhibition were observed with an unfused IkBa protein (data not shown). Note that the apparent reduction of the basal NF-kB activity in lane 2 of Figure 5c is because of the unequal protein loading as indicated by the much weaker nonspecific DNA complex Specific inhibition of NF-jB through VP22-IjBa C Stroh et al other cellular targets and signaling pathways. Certainly, a more specific inhibition of NF-kB is obtained by the use of antisense oligonucleotides, for instance, against the NF-kB RelA subunit, which abrogated experimental colitis and arthritis in mouse models (Neurath et al., 1996; Tomita et al., 1999) . However, such antisense approaches are generally hampered by the low efficacy of intracellular delivery and the limited bioavailability of oligonucleotides in vivo.
Protein transduction seems to be a promising alternative for effective and tissue-specific delivery of pharmacologically active proteins or peptides. Several different vehicles have been exploited to transport target proteins into cells including VP22, HIV-1 Tat, and Antennapedia homeodomain protein. Even though protein transduction technology emerged only a few years ago, it has already proven its prospects in several animal models (Schwarze and Dowdy, 2000) . For instance, a fusion protein of the Tat PTD with bgalactosidase could be detected in all tissues including the brain of intraperitoneally injected mice (Schwarze et al., 1999) . Tat PTD-mediated intracellular delivery of a peptide that interferes with assembly of the IKK complex has been recently also used to block inducible NF-kB activation (May et al., 2000) . As IKK phosphorylates different members of the IkB family that exert distinct biological roles, such approaches will presumably lack high specificity. It can also not be excluded that the IKK complex phosphorylates and regulates substrates other than IkB proteins. In this context, IKKa has recently been found to control keratinocyte differentiation independently of NF-kB (Hu et al., 2001) . Furthermore, blocking IKK activity would not inhibit constitutive NF-kB activation caused by defective IkBa activity that has been found in a variety of solid tumors (Rayet and Gelinas, 1999) . More specific targets for inhibition of NF-kB are therefore IkB proteins and the transcription factor itself. Recently, a Tat-PTD fusion with a nonphosphorylatable and degradation-resistant IkBa a mutant was generated (Kabouridis et al., 2002) . The protein was taken up into cells after exogenous application and proved to be a potent and specific inhibitor of inducible NF-kB activation.
We chose VP22 as a vehicle for an NF-kB-inhibitory protein because of its unique ability of intercellular trafficking. The mechanism of VP22 spreading is only poorly understood, but occurs presumably via a nonclassical Golgi-independent pathway involving the actin cytoskeleton. An intercellular spread of VP22 has been demonstrated by transfection with fusion proteins including GFP, p53, and the suicide enzyme cytosine deaminase (Elliott and O'Hare, 1997; Phelan et al., 1998; Wybranietz et al., 2001) . The transport of VP22 proteins is not restricted to distinct tissues or cell types (Wybranietz et al., 1999) . In mouse tumor models, it was shown that adenovirally expressed p53-VP22 led to increased antitumor activity and apoptosis of tumor cells compared to p53 alone (Wills et al., 2001; Zender et al., 2002) . Thus, the enhanced in vivo delivery of VP22 fusion might improve gene therapeutic approaches.
Even though we produced a large panel of different VP22-IkBa versions, unexpectedly, we could not take advantage of transcellular migration, since none of the VP22-IkBa constructs was exported from primary expressing cells. However, despite this failure, recombinant VP22-IkBa proteins were readily imported into cells after exogenous administration, clearly demonstrating that cellular spreading and import of VP22 are two independent processes. Both the spreading and import were not affected by the orientation of the VP22 fusion or other parameters such as the presence of fetal calf serum. In addition, we generated several VP22 constructs that were fused to a dominant-negative mutant of the NF-kB subunit RelA lacking the transactivation domain (data not shown). Although similar to our previous study (Grimm et al., 1996) , this RelA mutant potently inhibited NF-kB after exogenous supply, it did not also undergo intercellular spreading after overexpression. Since intercellular spreading of VP22 proteins occurs from the cytoplasm of the original expressing cell, the lack of spreading of the NF-kB RelA mutant might be explained by its exclusive nuclear localization (data not shown). The reason why VP22-IkBa, which was distributed both in the cytoplasm and nucleus, did not exert intracellular trafficking activity, remains unknown. It has been recently described that an N-terminal but not Cterminal fusion of VP22 with cytosine deaminase undergoes spreading (Wybranietz et al., 2001) . Thus, only empirical analysis might elucidate the functionality of the fusion products.
The uptake from the extracellular environment through the plasma membrane into the cell is the common feature of proteins with transduction potential. So far, little attention has been paid to the classical protein transduction property of VP22, and to our knowledge this study is one of the first reports showing that purified recombinant fusion proteins are efficiently imported into cells. We found that a concentration of 40 nm (3 mg/ml) of baculovirally expressed VP22-IkBa was sufficient to inhibit both the intrinsic basal as well as the inducible activity of NF-kB, which was not only seen in DNA binding but also in reporter gene assays.
Efficient inhibition of NF-kB through delivery of Tat-PTD-IkBa has been reported to require concentrations of 400 nm of the protein and preincubation times of several hours (Kabouridis et al., 2002) . Less specific approaches even require inhibitor doses in the micro-to millimolar range (Pierce et al., 1997; Fujihara et al., 2000; May et al., 2000; Swinney et al., 2002) . Thus, the VP22-IkBa system proved to be not only specific, but also highly potent. Recently, a new peptide carrier, Pep-1, for the delivery of biologically active proteins into mammalian cells has been described (Morris et al., 2001) . In contrast to other protein transduction systems that require the fusion of proteins, Pep-1 forms noncovalent complexes with the proteins to be imported. GFP, b-galactosidase, and antibodies were shown to be delivered into cells by Pep-1. However, to achieve effective import of these proteins, Pep-1 concentrations of more than 1 mm were necessary, which underlines the high protein transduction potential of VP22-IkBa.
In contrast to mammalian and baculoviral expression systems, it was not possible to express full-length VP22 in bacteria. Nevertheless, similar to a recent report (Kueltzo et al., 2002) , reduction to the C-terminal half of VP22 made it possible to express VP22D159-IkBa and ÀD N IkBa, which were efficiently taken up into cells. We even showed that the last 34 C-terminal amino acids of VP22 are sufficient for specific import. Unexpectedly, the bacterial proteins were not able to interact with NFkB inside cells, presumably because of massive intracellular aggregation or the lack of post-translational or other modifications. Although, in contrast to bacteria, baculoviral expression VP22-IkBa resulted in considerably lower yields, this system could be successfully employed to produce highly purified and selective vehicles for NF-kB inhibition. Together, our results do not only add important new information for VP22 protein transduction, but also provide a versatile tool for the inhibition of NF-kB. The selective and efficient delivery of functional VP22-IkBa will be helpful to decipher the role of NF-kB in diverse biological processes and might also offer possibilities for potential applications in future antiinflammatory and anticancer therapies.
